Clinical features, pathophysiology and management of fatal familial insomnia

References

• Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136–144.
   Google Scholar
• Kubler E, Oesch B, Alex JR. Diagnosis of prion diseases. Brit Med Bull. 2003;66:267–279.
   Google Scholar
• Knight R. The diagnosis of prion diseases. Parasitology. 1998;117(Suppl):S3–11.
   Google Scholar
• Federspil PA, Federspil P, Plinkert PK. [Diagnosis of prion diseases]. Hno. 2002;50(4):327–331.
   Google Scholar
• Budka H. Neuropathology of prion diseases. Br Med Bull. 2003;66:121–130.
   Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95(23):13363–13383.
   Google Scholar
• Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001;411(6839):810–813.
   Google Scholar
• Atarashi R, Moore RA, Sim VL, et al. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat Methods. 2007;4(8):645–650.
   Google Scholar
• Concha-Marambio L, Pritzkow S, Moda F, et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016;8(370):370ra183.
   Google Scholar
• Moda F, Gambetti P, Notari S, et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med. 2014;371(6):530–539.
   Google Scholar
• McGuire LI, Poleggi A, Poggiolini I, et al. Cerebrospinal fluid real-time quaking-induced conversion is a robust and reliable test for sporadic creutzfeldt-jakob disease: an international study. Ann Neurol. 2016;80(1):160–165.
   Google Scholar
• Verde F, Ticozzi N, Messina S, et al. MRI abnormalities found 1 year prior to symptom onset in a case of Creutzfeldt-Jakob disease. J Neurol. 2016;263(3):597–599.
   Google Scholar
• Orru CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med. 2014;371(6):519–529.
   Google Scholar
• Lugaresi E, Medori R, Montagna P, et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med. 1986;315(16):997–1003.
   Google Scholar
• Medori R, Tritschler HJ, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med. 1992;326(7):444–449.
   Google Scholar
• Montagna P, Cortelli P, Avoni P, et al. Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene. Brain Pathol. 1998;8(3):515–520.
   Google Scholar
• Monari L, Chen SG, Brown P, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism. Proc Natl Acad Sci U S A. 1994;91(7):2839–2842.
   Google Scholar
• McLean CA, Storey E, Gardner RJ, et al. The D178N (cis-129M) “fatal familial insomnia” mutation associated with diverse clinicopathologic phenotypes in an Australian kindred. Neurology. 1997;49(2):552–558.
   Google Scholar
• Taniwaki Y, Hara H, Doh-Ura K, et al. Familial Creutzfeldt-Jakob disease with D178N-129M mutation of PRNP presenting as cerebellar ataxia without insomnia. J Neurol Neurosurg Psychiatry. 2000;68(3):388.
   Google Scholar
• Johnson MD, Vnencak-Jones CL, McLean MJ. Fatal familial insomnia: clinical and pathologic heterogeneity in genetic half brothers. Neurology. 1998;51(6):1715–1717.
   Google Scholar
• Parchi P, Capellari S, Chin S, et al. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology. 1999;52(9):1757–1763.
   Google Scholar
• Mastrianni JA, Nixon R, Layzer R, et al. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med. 1999;340(21):1630–1638.
   Google Scholar
• Scaravilli F, Cordery RJ, Kretzschmar H, et al. Sporadic fatal insomnia: a case study. Ann Neurol. 2000;48(4):665–668.
   Google Scholar
• Guaraldi P, Calandra-Buonaura G, Terlizzi R, et al. Oneiric stupor: the peculiar behaviour of agrypnia excitata. Sleep Med. 2011;12(Suppl 2):S64–7.
   Google Scholar
• Gambetti P, Parchi P, Petersen RB, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. Brain Pathol. 1995;5(1):43–51.
   Google Scholar
• Montagna P, Gambetti P, Cortelli P, et al. Familial and sporadic fatal insomnia. Lancet Neurol. 2003;2(3):167–176.
   Google Scholar
• Krasnianski A, Sanchez Juan P, Ponto C, et al. A proposal of new diagnostic pathway for fatal familial insomnia. J Neurol Neurosurg Psychiatry. 2014;85(6):654–659.
   Google Scholar
• Tinuper P, Montagna P, Medori R, et al. The thalamus participates in the regulation of the sleep-waking cycle. A clinico-pathological study in fatal familial thalamic degeneration. Electroencephalogr Clin Neurophysiol. 1989;73(2):117–123.
   Google Scholar
• Calandra-Buonaura G, Provini F, Guaraldi P, et al. Cardiovascular autonomic dysfunctions and sleep disorders. Sleep Med Rev. 2016;26:43–56.
   Google Scholar
• Cortelli P, Perani D, Montagna P, et al. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006;129(Pt 3):668–675.
   Google Scholar
• Cortelli P, Perani D, Parchi P, et al. Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein. Neurology. 1997;49(1):126–133.
   Google Scholar
• Cortelli P, Fabbri M, Calandra-Buonaura G, et al. Gait disorders in fatal familial insomnia. Mov Disord. 2014;29(3):420–424.
   Google Scholar
• Peng B, Zhang S, Dong H, et al. histopathological and genetic studies in a case of fatal familial insomnia with review of the literature. Int J Clin Exp Pathol. 2015;8(9):10171–10177.
   Google Scholar
• Schenkein J, Montagna P. Self management of fatal familial insomnia. Part 1: what is FFI? MedGenMed. 2006;8(3):65.
   Google Scholar
• Shi XH, Han J, Zhang J, et al. Clinical, histopathological and genetic studies in a family with fatal familial insomnia. Infect Genet Evol. 2010;10(2):292–297.
   Google Scholar
• Macchi G, Rossi G, Abbamondi AL, et al. Diffuse thalamic degeneration in fatal familial insomnia. A morphometric study. Brain Res. 1997;771(1):154–158.
   Google Scholar
• Almer G, Hainfellner JA, Brucke T, et al. Fatal familial insomnia: a new Austrian family. Brain. 1999;122(Pt 1):5–16.
   Google Scholar
• Parchi P, Castellani R, Cortelli P, et al. Regional distribution of protease-resistant prion protein in fatal familial insomnia. Ann Neurol. 1995;38(1):21–29.
   Google Scholar
• Guentchev M, Wanschitz J, Voigtlander T, et al. Selective neuronal vulnerability in human prion diseases. Fatal familial insomnia differs from other types of prion diseases. Am J Pathol. 1999;155(5):1453–1457.
   Google Scholar
• Liberski PP, Streichenberger N, Giraud P, et al. Ultrastructural pathology of prion diseases revisited: brain biopsy studies. Neuropathol Appl Neurobiol. 2005;31(1):88–96.
   Google Scholar
• Stahl N, Borchelt DR, Hsiao K, et al. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell. 1987;51(2):229–240.
   Google Scholar
• Gasperini L, Meneghetti E, Legname G, et al. In absence of the cellular prion protein, alterations in copper metabolism and copper-dependent oxidase activity affect iron distribution. Front Neurosci. 2016;10:437.
   Google Scholar
• Millhauser GL. Copper and the prion protein: methods, structures, function, and disease. Annu Rev Phys Chem. 2007;58:299–320.
   Google Scholar
• Viles JH, Klewpatinond M, Nadal RC. Copper and the structural biology of the prion protein. Biochem Soc Trans. 2008;36(Pt 6):1288–1292.
   Google Scholar
• Westergard L, Christensen HM, Harris DA. The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta. 2007;1772(6):629–644.
   Google Scholar
• Mouillet-Richard S, Ermonval M, Chebassier C, et al. Signal transduction through prion protein. Science. 2000;289(5486):1925–1928.
   Google Scholar
• Jeffrey M, Halliday WG, Bell J, et al. Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol. 2000;26(1):41–54.
   Google Scholar
• Roucou X, Gains M, LeBlanc AC. Neuroprotective functions of prion protein. J Neurosci Res. 2004;75(2):153–161.
   Google Scholar
• Milhavet O, Lehmann S. Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Res Brain Res Rev. 2002;38(3):328–339.
   Google Scholar
• Brown DR, Wong BS, Hafiz F, et al. Normal prion protein has an activity like that of superoxide dismutase. Biochem J. 1999;344(Pt 1):1–5.
   Google Scholar
• Rieger R, Edenhofer F, Lasmezas CI, et al. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med. 1997;3(12):1383–1388.
   Google Scholar
• Khosravani H, Zhang Y, Tsutsui S, et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J Gen Physiol. 2008;131(6):i5.
   Google Scholar
• Gasperini L, Meneghetti E, Pastore B, et al. Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. Antioxid Redox Signal. 2015;22(9):772–784.
   Google Scholar
• Black SA, Stys PK, Zamponi GW, et al. Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity. Front Cell Dev Biol. 2014;2:45.
   Google Scholar
• Beraldo FH, Arantes CP, Santos TG, et al. Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin gamma1 chain. Faseb J. 2011;25(1):265–279.
   Google Scholar
• Beraldo FH, Arantes CP, Santos TG, et al. Role of alpha7 nicotinic acetylcholine receptor in calcium signaling induced by prion protein interaction with stress-inducible protein 1. J Biol Chem. 2010;285(47):36542–36550.
   Google Scholar
• Kuffer A, Lakkaraju AK, Mogha A, et al. The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6. Nature. 2016;536(7617):464–468.
   Google Scholar
• Turk E, Teplow DB, Hood LE, et al. Purification and properties of the cellular and scrapie hamster prion proteins. Eur J Biochem. 1988;176(1):21–30.
   Google Scholar
• Maiti NR, Surewicz WK. The role of disulfide bridge in the folding and stability of the recombinant human prion protein. J Biol Chem. 2001;276(4):2427–2431.
   Google Scholar
• Rudd PM, Endo T, Colominas C, et al. Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc Natl Acad Sci U S A. 1999;96(23):13044–13049.
   Google Scholar
• Locht C, Chesebro B, Race R, et al. Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A. 1986;83(17):6372–6376.
   Google Scholar
• Caughey B, Race RE, Ernst D, et al. Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol. 1989;63(1):175–181.
   Google Scholar
• Bate C, Nolan W, McHale-Owen H, et al. Sialic acid within the glycosylphosphatidylinositol anchor targets the cellular prion protein to synapses. J Biol Chem. 2016;291(33):17093–17101.
   Google Scholar
• Zahn R, Liu A, Luhrs T, et al. NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A. 2000;97(1):145–150.
   Google Scholar
• Calzolai L, Zahn R. Influence of pH on NMR structure and stability of the human prion protein globular domain. J Biol Chem. 2003;278(37):35592–35596.
   Google Scholar
• Knaus KJ, Morillas M, Swietnicki W, et al. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat Struct Biol. 2001;8(9):770–774.
   Google Scholar
• Petersen RB, Parchi P, Richardson SL, et al. Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. J Biol Chem. 1996;271(21):12661–12668.
   Google Scholar
• Apetri AC, Surewicz WK. Kinetic intermediate in the folding of human prion protein. J Biol Chem. 2002;277(47):44589–44592.
   Google Scholar
• Apetri AC, Surewicz K, Surewicz WK. The effect of disease-associated mutations on the folding pathway of human prion protein. J Biol Chem. 2004;279(17):18008–18014.
   Google Scholar
• Swietnicki W, Petersen RB, Gambetti P, et al. Familial mutations and the thermodynamic stability of the recombinant human prion protein. J Biol Chem. 1998;273(47):31048–31052.
   Google Scholar
• Liemann S, Glockshuber R. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry. 1999;38(11):3258–3267.
   Google Scholar
• Kovacs GG, Puopolo M, Ladogana A, et al. Genetic prion disease: the EUROCJD experience. Hum Genet. 2005;118(2):166–174.
   Google Scholar
• Mead S. Prion disease genetics. Eur J Hum Genet. 2006;14(3):273–281.
   Google Scholar
• Oesch B, Westaway D, Walchli M, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell. 1985;40(4):735–746.
   Google Scholar
• Meyer RK, McKinley MP, Bowman KA, et al. Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci U S A. 1986;83(8):2310–2314.
   Google Scholar
• Safar J, Prusiner SB. Molecular studies of prion diseases. Prog Brain Res. 1998;117:421–434.
   Google Scholar
• Parchi P, Zou W, Wang W, et al. Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci U S A. 2000;97(18):10168–10172.
   Google Scholar
• Peretz D, Williamson RA, Legname G, et al. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron. 2002;34(6):921–932.
   Google Scholar
• Huang Z, Gabriel JM, Baldwin MA, et al. Proposed three-dimensional structure for the cellular prion protein. Proc Natl Acad Sci U S A. 1994;91(15):7139–7143.
   Google Scholar
• Nguyen J, Baldwin MA, Cohen FE, et al. Prion protein peptides induce alpha-helix to beta-sheet conformational transitions. Biochemistry. 1995;34(13):4186–4192.
   Google Scholar
• Watanabe Y, Hiraoka W, Shimoyama Y, et al. Instability of familial spongiform encephalopathy-related prion mutants. Biochem Biophys Res Commun. 2008;366(1):244–249.
   Google Scholar
• Gauczynski S, Krasemann S, Bodemer W, et al. Recombinant human prion protein mutants huPrP D178N/M129 (FFI) and huPrP+9OR (fCJD) reveal proteinase K resistance. J Cell Sci. 2002;115(Pt 21):4025–4036.
   Google Scholar
• Brown P, Kenney K, Little B, et al. Intracerebral distribution of infectious amyloid protein in spongiform encephalopathy. Ann Neurol. 1995;38(2):245–253.
   Google Scholar
• Zarranz JJ, Digon A, Atares B, et al. Phenotypic variability in familial prion diseases due to the D178N mutation. J Neurol Neurosurg Psychiatry. 2005;76(11):1491–1496.
   Google Scholar
• Tzaban S, Friedlander G, Schonberger O, et al. Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes. Biochemistry. 2002;41(42):12868–12875.
   Google Scholar
• Jackson WS, Borkowski AW, Faas H, et al. Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron. 2009;63(4):438–450.
   Google Scholar
• Bouybayoune I, Mantovani S, Del Gallo F, et al. Transgenic fatal familial insomnia mice indicate prion infectivity-independent mechanisms of pathogenesis and phenotypic expression of disease. Plos Pathog. 2015;11(4):e1004796.
   Google Scholar
• Tateishi J, Brown P, Kitamoto T, et al. First experimental transmission of fatal familial insomnia. Nature. 1995;376(6539):434–435.
   Google Scholar
• Collinge J, Palmer MS, Sidle KC, et al. Transmission of fatal familial insomnia to laboratory animals. Lancet. 1995;346(8974):569–570.
   Google Scholar
• Telling GC, Parchi P, DeArmond SJ, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science. 1996;274(5295):2079–2082.
   Google Scholar
• Stockel J, Safar J, Wallace AC, et al. Prion protein selectively binds copper(II) ions. Biochemistry. 1998;37(20):7185–7193.
   Google Scholar
• Sano K, Satoh K, Atarashi R, et al. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. Plos One. 2013;8(1):e54915.
   Google Scholar
• Orru CD, Groveman BR, Raymond LD, et al. Bank vole prion protein as an apparently universal substrate for RT-QuIC-based detection and discrimination of prion strains. Plos Pathog. 2015;11(6):e1004983.
   Google Scholar
• Cramm M, Schmitz M, Karch A, et al. Stability and reproducibility underscore utility of RT-QuIC for diagnosis of Creutzfeldt-Jakob disease. Mol Neurobiol. 2016;53(3):1896–1904.
   Google Scholar
• Cramm M, Schmitz M, Karch A, et al. Characteristic CSF prion seeding efficiency in humans with prion diseases. Mol Neurobiol. 2015;51(1):396–405.
   Google Scholar
• Llorens F, Thune K, Schmitz M, et al. Identification of new molecular alterations in fatal familial insomnia. Hum Mol Genet. 2016;25(12):2417–2436.
   Google Scholar
• Schmitz M, Cramm M, Llorens F, et al. The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases. Nat Protoc. 2016;11(11):2233–2242.
   Google Scholar
• Frobose T, Slawik H, Schreiner R, et al. Agomelatine improves sleep in a patient with fatal familial insomnia. Pharmacopsychiatry. 2012;45(1):34–36.
   Google Scholar
• Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain. 2006;129(Pt 9):2241–2265.
   Google Scholar
• Warner RG, Hundt C, Weiss S, et al. Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem. 2002;277(21):18421–18430.
   Google Scholar
• Kimberlin RH, Walker CA. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother. 1986;30(3):409–413.
   Google Scholar
• Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol. 1993;67(2):643–650.
   Google Scholar
• Caughey WS, Raymond LD, Horiuchi M, et al. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A. 1998;95(21):12117–12122.
   Google Scholar
• Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science. 2000;287(5457):1503–1506.
   Google Scholar
• Caughey B, Ernst D, Race RE. Congo red inhibition of scrapie agent replication. J Virol. 1993;67(10):6270–6272.
   Google Scholar
• Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol. 1995;69(1):506–508.
   Google Scholar
• Adjou KT, Privat N, Demart S, et al. MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters. J Comp Pathol. 2000;122(1):3–8.
   Google Scholar
• Imberdis T, Heeres JT, Yueh H, et al. Identification of anti-prion compounds using a novel cellular assay. J Biol Chem. 2016;291(50):26164–26176.
   Google Scholar
• Soto C, Kascsak RJ, Saborio GP, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet. 2000;355(9199):192–197.
   Google Scholar
• Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science. 1997;276(5315):1119–1122.
   Google Scholar
• Forloni G, Iussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A. 2002;99(16):10849–10854.
   Google Scholar
• Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol. 2000;300(5):1309–1322.
   Google Scholar
• Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology. 2004;62(5):714–718.
   Google Scholar
• Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8(4):334–344.
   Google Scholar
• Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81(23):2015–2023.
   Google Scholar
• Bone I, Belton L, Walker AS, et al. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol. 2008;15(5):458–464.
   Google Scholar
• Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology. 2009;29(5):632–636.
   Google Scholar
• de Luigi A, Colombo L, Diomede L, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. Plos One. 2008;3(3):e1888.
   Google Scholar
• Forloni G, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature. 1993;362(6420):543–546.
   Google Scholar
• Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256–265.
   Google Scholar
• Haik S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150–158.
   Google Scholar
• Assar H, Topakian R, Weis S, et al. A case of variably protease-sensitive prionopathy treated with doxycyclin. J Neurol Neurosurg Psychiatry. 2015;86(7):816–818.
   Google Scholar
• Vetrugno V, Puopolo M, Cardone F, et al. The future for treating Creutzfeldt-Jakob disease. Expert Opin Orphan D. 2015;3(1):57–74.
   Google Scholar
• Forloni G, Tettamanti M, Lucca U, et al. Preventive study in subjects at risk of fatal familial insomnia: innovative approach to rare diseases. Prion. 2015;9(2):75–79.
   Google Scholar
• Redaelli V, Bistaffa E, Zanusso G, et al. Detection of prion seeding activity in the olfactory mucosa of patients with Fatal Familial Insomnia. Sci Rep. 2017;7:46269. doi: 10.1038/srep46269.
   Google Scholar